Education
About Us
Working with TipRanks
Follow Us
CANbridge Pharmaceuticals Inc. (HK:1228)
:1228
1228 Stock Chart & Stats
HK$2.52
<HK$0.01(5.93%)
At close: 4:00 PM EST
HK$2.52
<HK$0.01(5.93%)
Day’s Range― - ―
52-Week RangeHK$0.12 - HK$3.50
Previous CloseN/A
Volume661.00K
Average Volume (3M)5.03M
Market Cap
HK$1.54B
Enterprise ValueHK$1.04B
Total Cash (Recent Filing)HK$1.96M
Total Debt (Recent Filing)HK$34.97M
Price to Earnings (P/E)―
Beta1.23
Next Earnings
Mar 26, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)0.16
Shares Outstanding511,222,230
10 Day Avg. Volume2,153,700
30 Day Avg. Volume5,027,972
Financial Highlights & Ratios
PEG Ratio>-0.01
Price to Book (P/B)-0.11
Price to Sales (P/S)0.62
P/FCF Ratio-0.43
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Focus On Rare Diseases And OncologyTargeting rare diseases and oncology is a durable strategic position: these areas have persistent unmet medical need, regulatory incentives, and potential for premium pricing. Success in these niches can create long-term, high-value revenue streams and durable market exclusivity.
Multiple Funding And Partnership ChannelsA diversified funding model — product sales plus partnerships, upfronts, milestones and royalties — structurally reduces single-source revenue risk, enables milestone-driven non-dilutive funding, and supports sustained development and commercialization if partnerships are executed.
Positive Gross Profit MarginsPositive gross margins indicate underlying product economics that could scale profitably once fixed R&D and SG&A are spread over higher revenue. If clinical candidates commercialize, this structural margin base supports sustainable operating profit improvement over the medium term.
Bears Say
Negative Equity And High LeverageNegative equity and high leverage are structural weaknesses: they limit borrowing capacity, raise refinancing risk, and constrain strategic flexibility. Long-term recovery requires substantial earnings improvement or capital raises, both of which can be difficult in volatile markets.
Persistently Negative Operating And Free Cash FlowConsistent negative operating and free cash flow forces ongoing reliance on external financing, increasing dilution risk and potentially delaying development timelines. Durable financial health requires a structural turnaround in cash generation or secured long-term funding sources.
Declining And Inconsistent Revenue TrendA steep, inconsistent revenue decline undermines the company's ability to scale and absorb fixed costs. Sustained negative top-line trends increase pressure on liquidity and raise execution risk for bringing pipeline products to market without steady commercial traction or larger partner support.
CANbridge Pharmaceuticals Inc. News
1228 FAQ
What was CANbridge Pharmaceuticals Inc.’s price range in the past 12 months?
CANbridge Pharmaceuticals Inc. lowest stock price was HK$0.12 and its highest was HK$3.50 in the past 12 months.
What is CANbridge Pharmaceuticals Inc.’s market cap?
CANbridge Pharmaceuticals Inc.’s market cap is HK$1.54B.
When is CANbridge Pharmaceuticals Inc.’s upcoming earnings report date?
CANbridge Pharmaceuticals Inc.’s upcoming earnings report date is Mar 26, 2026 which is in 30 days.
How were CANbridge Pharmaceuticals Inc.’s earnings last quarter?
CANbridge Pharmaceuticals Inc. released its earnings results on Aug 31, 2025. The company reported HK$0.158 earnings per share for the quarter, beating the consensus estimate of N/A by HK$0.158.
Is CANbridge Pharmaceuticals Inc. overvalued?
According to Wall Street analysts CANbridge Pharmaceuticals Inc.’s price is currently Overvalued.
Does CANbridge Pharmaceuticals Inc. pay dividends?
CANbridge Pharmaceuticals Inc. does not currently pay dividends.
What is CANbridge Pharmaceuticals Inc.’s EPS estimate?
CANbridge Pharmaceuticals Inc.’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does CANbridge Pharmaceuticals Inc. have?
CANbridge Pharmaceuticals Inc. has 511,222,230 shares outstanding.
What happened to CANbridge Pharmaceuticals Inc.’s price movement after its last earnings report?
CANbridge Pharmaceuticals Inc. reported an EPS of HK$0.158 in its last earnings report, beating expectations of N/A. Following the earnings report the stock price went up 6.25%.
Which hedge fund is a major shareholder of CANbridge Pharmaceuticals Inc.?
Currently, no hedge funds are holding shares in HK:1228
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
CANbridge Pharmaceuticals Inc. Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Technicals
SMA
Positive
20 days / 200 days
Momentum
696.29%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
-56.79%
Trailing 12-Months
Company Description
CANbridge Pharmaceuticals Inc.
CANbridge Pharmaceuticals Inc., a biopharmaceutical company, engages in the research, development, and commercialization of therapies for rare diseases and oncology indications worldwide. The company offers Hunterase, an enzyme replacement therapy for the treatment of Hunter syndrome; NERLYNX (Neratinlib), a potent irreversible tyrosine kinase inhibitor for HER2-positive breast cancer; and Caphosol Mouth Rinse for temporary and persistent dryness of the mouth and throat. It also engages in the development of CAN008, an artificially engineered antibody-like fully human fusion protein for the treatment of glioblastoma multiforme; CAN108, an orally absorbed reversible inhibitor of the ileal bile acid transporter to treat rare cholestatic liver diseases; CAN106, a humanized monoclonal antibody against complement C5 being developed for the treatment of complement-mediated diseases; CAN103, a recombinant human enzyme replacement therapy (ERT); CAN104, a recombinant human ERT; CAN105, a bispecific antibody; CAN201, a gene therapy program that utilizes adeno-associated virus (AAV) sL65 capsid; and CAN202, a gene therapy program utilizing AAV sL65 capsid. The company was founded in 2012 and is headquartered in Beijing, China.
Technical Analysis
Kintor Pharmaceutical Ltd
―
JW (Cayman) Therapeutics Co. Ltd.
―
Clover Biopharmaceuticals Ltd.
―
Sirnaomics Ltd.
―
Transcenta Holding Limited
―